ICON selected as Data Management Partner for the 100,000 Genomes
Project
DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has been selected by Genomics
England as data management partner for the 100,000
Genomes Project.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160209005247/en/
A ground-breaking project announced by the British Prime Minister David
Cameron in 2012, the 100,000 Genomes Project is sequencing 100,000 whole
genomes from 70,000 National Health Service (NHS) cancer and rare
disease patients and their families. It aims to demonstrate a new
genomic medicine service for the NHS to support better diagnosis and
more personalised treatments for patients. De-identified data from the
100,000 Genomes Project will also be made available to
approved researchers from industry to help accelerate the
development of new treatments and diagnostic tests that are targeted at
the genetic characteristics of individual patients.
As Genomics England's data management partner, ICON will use its
powerful data management capabilities, and understanding of the growing
role genomics data will have in clinical trials, to validate clinical
data from the 70,000 participating patients and their families. This
work will take place within the secure Genomics England data environment.
"We are very proud that our genomics knowledge and our capabilities
in securely managing large clinical and real world datasets have been
chosen by Genomics England for such an important and transformative
project," commented Professor Brendan Buckley, ICON's Chief Medical
Officer. "Our partnership with Genomics England demonstrates our
commitment to partnering with industry and government organisations in
new and innovative ways to improve patient care by accelerating the
development of targeted and personalised medicines that tackle complex
diseases. Genomics England's selection of ICON also reaffirms ICON as a
trusted partner to government organisations as well as the world's top
pharma, biotech and medical device companies."
James Peach, Managing Director for the 100,000 Genomes Project Main
Programme at Genomics England said: "We are delighted to be
partnering with ICON. Their renowned expertise in data management will
be fundamental in driving scientific research and accelerating the
return of results for NHS patients."
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. ICON has headquarters in
Dublin Ireland, and employs over 700 staff in the UK from offices in
London, Marlow, Eastleigh, Abingdon and Edinburgh. Globally, ICON
operates from 89 locations in 38 countries and has approximately 11,900
employees. Further information is available at www.iconplc.com
About Genomics England
Genomics England is a company owned by the Department of Health and was
set up to deliver the 100,000 Genomes Project. This flagship project
will sequence 100,000 whole genomes from NHS patients and their families
by 2017. Genomics England has four main aims:
-
To bring benefit to patients
-
To create an ethical and transparent programme based on consent
-
To enable new scientific discovery and medical insights
-
To kick-start the development of a UK genomics industry
The project is focusing on patients with rare diseases and their
families, as well as patients with common cancers. More information is
at www.genomicsengland.co.uk
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-G
View source version on businesswire.com: http://www.businesswire.com/news/home/20160209005247/en/
ICON Media Contact
Pippa Chester
Weber Shandwick
+44
(0) 207 067 0571
PChester@webershandwick.com
or
Genomics
England Media Contact
Katrina Nevin-Ridley
Director of
Communications
Genomics England
+44-(0)207 882 6493
katrina.nevin-ridley@genomicsengland.co.uk
Source: ICON plc
News Provided by Acquire Media
